Regeneron (REGN) Tops Q2 EPS by 39c, beats revenue

Regeneron (NASDAQ: REGN) reported Q2 EPS of $10.24, $0.39 better than the analyst estimate of $9.85. Revenue for the quarter came in at $3.16 billion versus the consensus estimate of $3.03 billion.

For earnings history and earnings-related data on Regeneron (REGN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c